Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.

Skip to main content

Table 5 Late adverse events following ultracentral radiation therapy according to the CTCAE v 5.0

From: Ten fraction hypofractionated stereotactic body radiotherapy for the management of ultracentral lung tumors: a retrospective analysis of dosimetry, outcomes, and toxicity

 

All patient (n = 78)

No prior in-field radiotherapy (n = 50)

Patients with thoracic re-irradiation (n = 28)

p-value

Grade 2

Grade 3

Grade 4

Grade 5

Grade 2

Grade 3

Grade 4

Grade 5

Grade 2

Grade 3

Grade 4

Grade 5

Pneumonitis

12

3

6

1

6

2

0.12

Esophagitis

1

1

0.36

Airway toxicity

1

2

1

2

0.7

Hemorrhage

3*

1*

2*

0.13

  1. All toxicity according to CTCAE v 5.0 scoring criteria
  2. *The three patients who experienced hemoptysis with subsequent death were scored as having “possibly” treated related toxicity (one patient underwent bronchoscopy with clear progression of disease, one patient had radiographic evidence of progressive bilateral hilar disease just prior to death, and one patient cause of death was uncertain)